Agilent reorganizes into three reportable segments: LSD, Applied, CrossLab

AGILENT TECHNOLOGIES, INC.

New segments: Life Sciences & Diagnostics Markets, Applied Markets, Agilent CrossLab, effective FY2025.
FY24 segment revenue: LSD $2,466M, CrossLab $2,747M, Applied $1,297M; operating margins 19.6%, 33.7%, 24.0%.
FY23 segment revenue: LSD $2,780M, CrossLab $2,656M, Applied $1,397M; LSD operating margin dropped from 24.2% to 19.6%.
Historical unaudited segment data provided for FY22, FY23, FY24; prior periods will be recast going forward.
No change to previously reported consolidated results; reorganization is market-focused, customer-centric.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.